Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial-Reference-Cited by-同舟云学术

Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial

Published:2014-05 Issue:6 Volume:15 Page:580-591
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

André Fabrice,O'Regan Ruth,Ozguroglu Mustafa,Toi Masakazu,Xu Binghe,Jerusalem Guy,Masuda Norikazu,Wilks Sharon,Arena Francis,Isaacs Claudine,Yap Yoon-Sim,Papai Zsuzsanna,Lang Istvan,Armstrong Anne,Lerzo Guillermo,White Michelle,Shen Kunwei,Litton Jennifer,Chen David,Zhang Yufen,Ali Shyanne,Taran Tetiana,Gianni Luca

Funder

Novartis

Novartis Pharmaceuticals Corporation

Publisher

Elsevier BV

Subject

Oncology

Reference36 articles.

1. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;Slamon;N Engl J Med,2001

3. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer;Esteva;J Clin Oncol,2002

4. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy;Montemurro;Oncologist,2006

5. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer;Bartsch;J Clin Oncol,2007

Cited by 437 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PI3K PROTAC overcomes the lapatinib resistance in PIK3CA-mutant HER2 positive breast cancer;Cancer Letters;2024-08

2. Bioinformatics and In Vitro Study Reveal ERα as The Potential Target Gene of Honokiol to Enhance Trastuzumab Sensitivity in HER2+ Trastuzumab-Resistant Breast Cancer Cells;Computational Biology and Chemistry;2024-08

3. Comprehensive landscape of gastric cancer-targeted therapy and identification of CSNK2A1 as a potential target;Heliyon;2024-08

4. Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer;Cancers;2024-07-24

5. Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine;Journal of Personalized Medicine;2024-07-03